Journal: Signal Transduction and Targeted Therapy

Article Title: Tumor biomarkers for diagnosis, prognosis and targeted therapy

doi: 10.1038/s41392-024-01823-2

Figure Lengend Snippet: The cancer invasion and metastasis and its targeted therapy. The tumor metastasis process consists of multiple steps. Initially, tumor cells invade the surrounding stroma and extracellular matrix from the primary tumor site, and then intravasate into the bloodstream or the lymphatics. Subsequently, tumor cells arrest in the circulation and arrive at distant organ sites, followed by extravasating and invading the parenchyma of distant tissues. Finally, tumor cells adapt to the new microenvironment and grow to form metastatic colonization. EMT is the basic embryonic developmental process that transforms polarized non-motile epithelial cells into motile and invasive mesenchymal cells. Multiple cellular stress conditions including hypoxia, inflammation, metabolic stress, and signaling cascades, can induce the expression of EMT transcription factors and prompt tumor metastasis. Meanwhile, MET amplification and mutation, the transcriptional dysregulation of c-MET, degradation deficiency, and abnormal HGF production result in the abnormal expression of HGF/c-MET and tumor progression. Various inhibitors including MMP inhibitors and HGF/c-MET inhibitors have been developed and emerging as promising tools in the suppression of tumor metastasis. c-MET mesenchymal-epithelial transition factor, EMT epithelial-mesenchymal transition, HGF hepatocyte growth factor, MMPs matrix metalloproteinases

Article Snippet: Other MMPs inhibitors such as COL-3 (NSC-683551), neovastat (AE-941), prinomastat (AG3340), BMS-275291, and metastat(COL-3), have been evaluated in clinical trials (Table ).

Techniques: Expressing, Amplification, Mutagenesis

Journal: Signal Transduction and Targeted Therapy

Article Title: Tumor biomarkers for diagnosis, prognosis and targeted therapy

doi: 10.1038/s41392-024-01823-2

Figure Lengend Snippet: The typical and clinically developed MMPs inhibitors in cancer therapy

Article Snippet: Other MMPs inhibitors such as COL-3 (NSC-683551), neovastat (AE-941), prinomastat (AG3340), BMS-275291, and metastat(COL-3), have been evaluated in clinical trials (Table ).

Techniques:

Journal: International Journal of Molecular Sciences

Article Title: Hypoxic Effects on Matrix Metalloproteinases’ Expression in the Tumor Microenvironment and Therapeutic Perspectives

doi: 10.3390/ijms242316887

Figure Lengend Snippet: Different Types of MMPIs Used in Cancer Treatment.

Article Snippet: Chemical modified tetracyclines , Metastat (COL-3) , MMP-1, MMP-2, MMP-8, MMP-9, MMP-13 , [ , , , , ] .

Techniques: Modification, Bioprocessing